CpE-based cancer treatments and diagnostics would ideally work best at nanomolar concentrations so that they can specifically target cancers overexpressing high-affinity CpE receptors, such as those involving claudin-4, -6, -9, and -17. The gene discussed is CLDN4; the disease is cancer.